Longer overall survival and similar safety profile were the endpoints in this NEJM piece, comparing those who received osimertinib with those who received a comparator EGFR-TKI.

Can transfusion independence for multiple weeks be possible in patients with myelodysplastic syndromes? Read on to discover promising information you can share with your patients about reducing the severity of their anemia.

NEJM explores the question: Are we, in fact, what we eat? Can the periodic flipping of a “metabolic switch” truly help patients?